Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Timothy Springer
Boston Children's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Morphic Therapeutic, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
In 2014, Dr. Springer helped found a company, Morphic Therapeutic, Inc. (“Company”), which was formed to develop small molecule antagonists of integrins based on newly defined chemotypes that block the integrin and binding site and have additional desired properties. The company will design new molecules, have them synthesized, and test their mode of antagonism, pharmacology, and in vivo therapeutic effects. Dr. Springer’s research in the subject grant includes determining crystal structures of integrin alpha5beta1.
Although Dr. Springer’s research focus as described in the grants specific aims is distinct from the Company’s work, it does have the potential to indirectly benefit Company aims to design, synthesize, and optimize new molecules. This is because Dr. Springer will be improving methods for obtaining high resolution crystal structures of a5b1 bound to large protein ligands. These methods may also be beneficial for determination of crystal structures with small molecules at MRT.
Structures and Conformational Equilibria of Integrin alpha5 beta1
The cell surface protein, integrin ?5?1, directs formation of new blood vessels during normal development of the vascular system and in tumors, and has also been implicated in mediating infections by bacteria that cause gastroenteritis and plague. This grant will explore the structure of integrin ?5?1 and how its binding partners, fibronectin and bacterial invasin, alter its shape. Insights obtained from this grant will be critical for developing more effective drugs to treat diseases that depend on the formation of new blood vessels, such as cancer.
Filed on May 14, 2019.
Tell us what you know about Timothy Springer's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Timothy Springer filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Timothy Springer | Boston Children's Hospital | Conflict of Interest | Morphic Therapeutics, Inc. | >$600,000 |
| Timothy Springer | Boston Children's Hospital | Conflict of Interest | Morphic Therapeutics, Inc. | $80,000 - $99,999 |
| Timothy Springer | Boston Children's Hospital | Conflict of Interest | Morphic Therapeutic, Inc. | $80,000 - $99,999 |
| Timothy Springer | Boston Children's Hospital | Conflict of Interest | Morphic Rock Therapeutic, Inc. | $0 - $4,999 |
| Tim Springer | Boston Children's Hospital | Conflict of Interest | Morphic Rock Therapeutics, Inc. | $0 - $4,999 |
| Timothy Spring | Boston Children's Hospital | Conflict of Interest | Morphic Rock Therapeutic, Inc. | $0 - $4,999 |
| Tim Springer | Boston Children's Hospital | Conflict of Interest | Morphic Rock Therapeutics, Inc. | Value cannot be readily determined |
| Tim Springer | Boston Children's Hospital | Conflict of Interest | Morphic Rock Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.